Our innovative platform technologies provide the capability to proactively create a national reserve of vaccines in a cost-effective and efficient manner unparalleled by our competitors. This has positioned us as a primary partner with the U.S. government for the development of critical anthrax and malaria vaccines.
Pfenex is developing Px563L, a novel anthrax vaccine candidate, in response to the United States government’s unmet demand for increased quantity, stability and dose sparing regimens of anthrax vaccine. The development of Px563L has been funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority, or BARDA, currently funded by a $143.5 million advanced development contract. Additionally, Px563L-SDI, a solid dose formulation of anthrax vaccine, has been funded by the National Institute of Allergy and Infectious Diseases, or NIAID, for up to a total of $22.9 million.
|PRE-CLINICAL||PHASE 1||PHASE 2|
FULLY FUNDED BY THE
*Development controlled by the US Government
Last Updated: 8/12/16